AAPL 167.04 -0.5714% MSFT 404.33 -1.8235% GOOG 157.46 0.3697% GOOGL 155.9725 0.3232% AMZN 179.17 -1.1639% NVDA 846.71 0.7568% META 501.8 1.544% TSLA 149.9 -3.5703% TSM 132.27 -4.8623% LLY 745.95 -0.642% V 271.36 -0.4877% AVGO 1258.99 -1.8431% JPM 181.25 0.6497% UNH 493.18 2.9625% NVO 122.75 -1.4294% WMT 59.27 -0.637% LVMUY 170.18 -0.3338% XOM 118.47 -0.1349% LVMHF 854.0 -0.4662% MA 454.7 -1.1865%
Last update at 2024-04-18T20:10:00Z
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 1122.00M | 1529.00M | 2680.00M | 3696.00M | 2729.00M |
Minority interest | - | - | - | - | - |
Net income | 917.00M | 1351.00M | 2160.00M | 3218.00M | 2153.00M |
Selling general administrative | 1704.00M | 1503.00M | 1666.00M | 1922.00M | 2013.00M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 3880.00M | 3922.00M | 4749.00M | 5503.00M | 5084.00M |
Reconciled depreciation | 212.00M | 195.00M | 157.00M | 354.00M | 1673.00M |
Ebit | 1478.00M | 1619.00M | 2849.00M | 3847.00M | 2825.00M |
Ebitda | 1690.00M | 1814.00M | 3006.00M | 4180.00M | 4498.00M |
Depreciation and amortization | 212.00M | 195.00M | 157.00M | 333.00M | 1673.00M |
Non operating income net other | - | - | - | - | - |
Operating income | 1478.00M | 1619.00M | 2849.00M | 3847.00M | 2706.00M |
Other operating expenses | 4469.00M | 4493.00M | 5317.00M | 3937.00M | 7071.00M |
Interest expense | 422.00M | 258.00M | 169.00M | 239.00M | 45.00M |
Tax provision | 205.00M | 178.00M | 520.00M | 337.00M | 576.00M |
Interest income | - | - | - | - | - |
Net interest income | -422.00000M | -258.00000M | - | 0.00000M | - |
Extraordinary items | 0.00000M | 0.00000M | -96.00000M | -88.00000M | - |
Non recurring | - | 3.00M | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 205.00M | 178.00M | 520.00M | 390.00M | 576.00M |
Total revenue | 6174.00M | 6304.00M | 8096.00M | 7777.00M | 9777.00M |
Total operating expenses | 2175.00M | 2111.00M | 1970.00M | 1663.00M | 2378.00M |
Cost of revenue | 2294.00M | 2382.00M | 3347.00M | 2274.00M | 4693.00M |
Total other income expense net | -356.00000M | -90.00000M | -169.00000M | -151.00000M | 23.00M |
Discontinued operations | - | - | -96.00000M | -88.00000M | -88.00000M |
Net income from continuing ops | 917.00M | 1351.00M | 2160.00M | 3218.00M | 2153.00M |
Net income applicable to common shares | 917.00M | 1351.00M | 2160.00M | 3218.00M | 2153.00M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Total assets | 10955.00M | 10681.00M | 10434.00M | 10548.00M | 10494.00M |
Intangible assets | 649.00M | 651.00M | 503.00M | 569.00M | 812.00M |
Earning assets | - | - | - | - | - |
Other current assets | 747.00M | 726.00M | 929.00M | 1078.00M | 871.00M |
Total liab | 11847.00M | 12189.00M | 11254.00M | 3513.00M | 4146.00M |
Total stockholder equity | -892.00000M | -1508.00000M | -820.00000M | 7035.00M | 6348.00M |
Deferred long term liab | - | 4.00M | - | - | - |
Other current liab | 1353.00M | 1206.00M | 942.00M | 1049.00M | 328.00M |
Common stock | 3.00M | 3.00M | 3.00M | 7949.00M | 7256.00M |
Capital stock | 3.00M | 3.00M | 3.00M | 0.00000M | - |
Retained earnings | -331.00000M | -998.00000M | -219.00000M | 0.00000M | - |
Other liab | 280.00M | 283.00M | 1879.00M | 2034.00M | 2567.00M |
Good will | 4603.00M | 4603.00M | 4603.00M | 4603.00M | 4603.00M |
Other assets | 539.00M | 464.00M | 347.00M | 659.00M | 714.00M |
Cash | 706.00M | 737.00M | 500.00M | 319.00M | 244.00M |
Cash and equivalents | 706.00M | 737.00M | 12.00M | 319.00M | 244.00M |
Total current liabilities | 2512.00M | 2597.00M | 1201.00M | 1341.00M | 1545.00M |
Current deferred revenue | 19.00M | - | - | - | - |
Net debt | 8207.00M | 8397.00M | -500.00000M | -215.00000M | - |
Short term debt | 8.00M | 9.00M | 1339.00M | 34.00M | 0.00000M |
Short long term debt | 8.00M | 9.00M | - | 34.00M | - |
Short long term debt total | 8913.00M | 9134.00M | - | 104.00M | 34.00M |
Other stockholder equity | -564.00000M | -513.00000M | 216.00M | 7949.00M | -908.00000M |
Property plant equipment | 1233.00M | 973.00M | 1089.00M | 762.00M | 651.00M |
Total current assets | 3931.00M | 3760.00M | 3434.00M | 3955.00M | 3714.00M |
Long term investments | - | - | - | - | - |
Net tangible assets | -6144.00000M | -6904.00000M | 380.00M | 1863.00M | 933.00M |
Short term investments | - | - | - | - | - |
Net receivables | 1475.00M | 1382.00M | 1092.00M | 1487.00M | 1605.00M |
Long term debt | 8905.00M | 9125.00M | 0.00000M | 70.00M | 34.00M |
Inventory | 1003.00M | 915.00M | 913.00M | 1071.00M | 994.00M |
Accounts payable | 1132.00M | 1382.00M | 259.00M | 258.00M | 289.00M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | -564.00000M | -513.00000M | -604.00000M | -914.00000M | - |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | 3.00M | 3.00M | - | - |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | -998.00000M | - | - | - |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 735.00M | 694.00M | 910.00M | 741.00M | - |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 7024.00M | 6921.00M | 7000.00M | 6593.00M | - |
Capital lease obligations | - | - | - | - | - |
Long term debt total | 8905.00M | 9125.00M | 0.00000M | 70.00M | 34.00M |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Investments | -420.00000M | -481.00000M | -258.00000M | -102.00000M | -69.00000M |
Change to liabilities | -237.00000M | 709.00M | 27.00M | -31.00000M | 20.00M |
Total cashflows from investing activities | -420.00000M | -481.00000M | -258.00000M | -102.00000M | -69.00000M |
Net borrowings | -108.00000M | 7728.00M | 1165.00M | -44.00000M | 59.00M |
Total cash from financing activities | -433.00000M | -1333.00000M | -2175.00000M | -2621.00000M | -4164.00000M |
Change to operating activities | 121.00M | 573.00M | -236.00000M | -214.00000M | -322.00000M |
Net income | 917.00M | 1351.00M | 2160.00M | 3306.00M | 2153.00M |
Change in cash | -31.00000M | 667.00M | -249.00000M | 75.00M | -527.00000M |
Begin period cash flow | 737.00M | 70.00M | 319.00M | 244.00M | 771.00M |
End period cash flow | 706.00M | 737.00M | 70.00M | 319.00M | 244.00M |
Total cash from operating activities | 858.00M | 2458.00M | 2187.00M | 2767.00M | 3687.00M |
Issuance of capital stock | - | - | - | - | - |
Depreciation | 212.00M | 195.00M | 157.00M | 333.00M | 1673.00M |
Other cashflows from investing activities | -117.00000M | -289.00000M | 20.00M | 7.00M | 32.00M |
Dividends paid | 290.00M | 145.00M | 145.00M | 145.00M | 145.00M |
Change to inventory | -220.00000M | -138.00000M | -29.00000M | -91.00000M | 44.00M |
Change to account receivables | -123.00000M | -277.00000M | 159.00M | 200.00M | 250.00M |
Sale purchase of stock | - | - | - | - | - |
Other cashflows from financing activities | -35.00000M | 436.00M | -2096.00000M | -2621.00000M | -4164.00000M |
Change to netincome | 181.00M | 210.00M | 67.00M | 107.00M | 35.00M |
Capital expenditures | 427.00M | 488.00M | 278.00M | 92.00M | 101.00M |
Change receivables | - | -277.00000M | - | - | - |
Cash flows other operating | - | 1759.00M | - | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | 702.00M | - | - | - |
Change in working capital | -452.00000M | 702.00M | -197.00000M | -672.00000M | -174.00000M |
Stock based compensation | 75.00M | 59.00M | 54.00M | 41.00M | 56.00M |
Other non cash items | 124.00M | 439.00M | 7.00M | -253.00000M | -58.00000M |
Free cash flow | 431.00M | 1970.00M | 1909.00M | 2675.00M | 3586.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
OGN Organon & Co |
-0.01 0.06% | 17.86 | 6.10 | 5.03 | 0.55 | 1.84 | 1.89 | 8.14 |
LLY Eli Lilly and Company |
-4.82 0.64% | 745.95 | 103.14 | 46.73 | 16.88 | 48.24 | 17.43 | 69.11 |
JNJ Johnson & Johnson |
0.97 0.67% | 145.74 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
ABBV AbbVie Inc |
0.41 0.25% | 164.66 | 42.38 | 13.68 | 4.88 | 22.14 | 5.72 | 31.93 |
MRK Merck & Company Inc |
-0.16 0.13% | 125.21 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
30 Hudson Street, Jersey City, NJ, United States, 07302
Name | Title | Year Born |
---|---|---|
Mr. Kevin Ali | CEO & Director | 1960 |
Mr. Matthew M. Walsh | Exec. VP & CFO | 1967 |
Ms. Susanne Gabriele Fiedler | Exec. VP & Chief Commercial Officer | 1968 |
Dr. Sandra Milligan J.D., M.D. | Exec. VP and Head of R&D | 1964 |
Ms. Rachel A. Stahler | Exec. VP & Chief Information Officer | 1976 |
Ms. Jennifer Halchak | VP of Investor Relations | NA |
Mr. Kirke Weaver | Gen. Counsel & Corp. Sec. | NA |
Mr. Aaron Falcione | Exec. VP & Chief HR Officer | 1971 |
Mr. Joseph T. Morrissey Jr. | Exec. VP and Head of Manufacturing & Supply | 1965 |
Mr. Vittorio Nisita | Exec. VP & Head of Global Bus. Services | 1968 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).